Antibodies and Peptides in Oncology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023
- Transparency Market Research
Antibodies and Peptides in Oncology Market: Brief Account
Immense potential lies in peptides for the treatment of cancer as it directly targets the cancer cells without harming the normal cells. This is targeted therapy and is far better than the traditional chemo therapy and thus driving the demand for antibodies and peptides in oncology. Peptides can be used directly as a cytotoxic agent or can carry the cytotoxic agents and radioisotopes, targeting only the cancer cells and this is boosting their demand in oncology. Peptide based hormonal therapy are now being used extensively for treating prostate cancer and breast cancer. It is expected that the global antibodies and peptides in oncology market will witness a significant growth in the years to come on account of the increasing number of deaths from cancer.
The report is a detailed overview of the antibodies and peptides in oncology market, taking into consideration all the factors impacting this market. Positive and negative influences on the market have been discussed in this report in great detail so that readers get an enhanced understanding of the various factors, which works well and those that go against the growth of this market. Key segments of the market are studied in detail and information such as leading, declining, and fastest growing segments are given.
Antibodies and Peptides in Oncology Market: Trends and Opportunities
In the years to come several products, which are currently in the pipeline are anticipated to emerge and this will create a huge opportunity for growth in the antibodies and peptides in oncology market. The growing range of cancer conditions and increasing number of patient population opting for advanced therapies are some of the other factors projected to boost the market throughout the forecast period. The number of patients and healthcare professionals having a positive outlook towards targeted therapy will also help the market to grow. In addition to this, the emergence of combination therapies will have a positive influence for the global antibodies and peptides in oncology market. However, the cost for research activities is very high and could pose a challenge for players in the antibodies and peptides in oncology market across the globe.
Antibodies and Peptides in Oncology Market: Geographical Analysis
On the basis of geography, the global antibodies and peptides in oncology market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. As per the report, North America led in the past in this market and is likely to continue to be in the leading position. The high rates of cancer among the people in the region and the heavy investments by large players for the research and development of cancer drugs are fueling the growth of the antibodies and peptides in oncology market in North America. Other factors encouraging the growth of the market in this region include favorable reimbursement policies and initiatives taken by government. In addition to North America, another region showing promising growth in the forecast period is Asia Pacific. The region is likely to witness a tremendous growth in the antibodies and peptides in oncology market on account of the growing awareness regarding advanced therapies and treatment options as well as an increase in healthcare expenditure.
Antibodies and Peptides in Oncology Market: Companies Mentioned
Some of the key global market participants present in the antibodies and peptides in oncology market are F. Hoffmann-La Roche Ltd, Novartis International AG, AstraZeneca plc, Merck & Co., Inc., Celgene Corporation, Johnson & Johnson Limited, Eli Lilly and Company, and GlaxoSmithKline.
Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.
Have query on this report?Make an Enquiry
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Pharmaceutical
PharmaceuticalChinese Markets for Mental Illness Drugs
PharmaceuticalChinese Markets for Anti-Dermatomycosis Skin Drugs
PharmaceuticalChinese Markets for Incretion Drugs
PharmaceuticalChinese Markets for Hypertension Drugs
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017